<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Barlow KM</submitter><funding>Canadian Institutes of Health Research</funding><pagination>271</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4227124</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>By the age of sixteen, one in five children will sustain a mild traumatic brain injury also known as concussion. Our research found that one in seven school children with mild traumatic brain injury suffer post-concussion syndrome symptoms for three months or longer. Post-concussion syndrome is associated with significant disability in the child and his/her family and yet there are no evidence-based medical treatments available. Melatonin has several potential mechanisms of action that could be useful following mild traumatic brain injury, including neuroprotective effects. The aim of this study is to determine if treatment with melatonin improves post-concussion syndrome in youths following mild traumatic brain injury. Our hypothesis is that treatment of post-concussion</pubmed_abstract><journal>Trials</journal><pubmed_title>A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial.</pubmed_title><pmcid>PMC4227124</pmcid><funding_grant_id>293375</funding_grant_id><pubmed_authors>Zemek R</pubmed_authors><pubmed_authors>Angelo M</pubmed_authors><pubmed_authors>Kirton A</pubmed_authors><pubmed_authors>Hill MD</pubmed_authors><pubmed_authors>Hutchison J</pubmed_authors><pubmed_authors>Buchhalter J</pubmed_authors><pubmed_authors>Nettel-Aguirre A</pubmed_authors><pubmed_authors>Esser M</pubmed_authors><pubmed_authors>Brooks BL</pubmed_authors><pubmed_authors>Richer L</pubmed_authors><pubmed_authors>Dewey D</pubmed_authors><pubmed_authors>Turley B</pubmed_authors><pubmed_authors>Kirk V</pubmed_authors><pubmed_authors>Emery CA</pubmed_authors><pubmed_authors>Barlow KM</pubmed_authors><pubmed_authors>Crawford S</pubmed_authors><pubmed_authors>Johnson D</pubmed_authors><pubmed_authors>Platt R</pubmed_authors><pubmed_authors>Seeger T</pubmed_authors><pubmed_authors>MacMaster FP</pubmed_authors></additional><is_claimable>false</is_claimable><name>A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial.</name><description>&lt;h4>Background&lt;/h4>By the age of sixteen, one in five children will sustain a mild traumatic brain injury also known as concussion. Our research found that one in seven school children with mild traumatic brain injury suffer post-concussion syndrome symptoms for three months or longer. Post-concussion syndrome is associated with significant disability in the child and his/her family and yet there are no evidence-based medical treatments available. Melatonin has several potential mechanisms of action that could be useful following mild traumatic brain injury, including neuroprotective effects. The aim of this study is to determine if treatment with melatonin improves post-concussion syndrome in youths following mild traumatic brain injury. Our hypothesis is that treatment of post-concussion</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Jul</publication><modification>2026-05-02T07:04:18.872Z</modification><creation>2026-04-07T17:41:43.481Z</creation></dates><accession>S-EPMC4227124</accession><cross_references><pubmed>25001947</pubmed><doi>10.1186/1745-6215-15-271</doi></cross_references></HashMap>